SCHEMBL1341287

SCHEMBL1341287

CS(=O)(=O)NCc1nc(NC(=O)Nc2ccccc2C(=O)C2CCCC2)sc1Sc1ccccn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.36
GRM4 Q14833 3/20 0.35
KDM4E B2RXH2 4/20 0.35
RAB9A P51151 2/20 0.35
HSD17B10 Q99714 2/20 0.35
ADORA3 P0DMS8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALOX15 P16050 1/20 0.35
LMNA P02545 1/20 0.34
MAPK10 P53779 1/20 0.34
RORC P51449 1/20 0.33
MAPT P10636 2/20 0.33
HPGD P15428 2/20 0.33
POLB P06746 1/20 0.33
NR4A1 P22736 1/20 0.33
HTT P42858 1/20 0.33
GUSB P08236 1/20 0.33
KMT2A Q03164 2/20 0.32
TP53 P04637 2/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1343535 0.94 GRM4 (0.35) ALDH1A1GRM4KDM4ERAB9AHSD17B10
SCHEMBL1340257 0.93 CCNE1 (0.34) ALDH1A1GRM4RAB9AADORA3L3MBTL1
SCHEMBL1341721 0.93 LMNA (0.37) ALDH1A1GRM4KDM4ERAB9AADORA3
SCHEMBL1343011 0.92 MAPT (0.35) ALDH1A1GRM4RAB9AMAPTHTT
SCHEMBL1342041 0.92 KDM4C (0.36) ALDH1A1GRM4RAB9AADORA3L3MBTL1
SCHEMBL1342044 0.92 ALDH1A1 (0.34) ALDH1A1GRM4RAB9AADORA3L3MBTL1
SCHEMBL1342860 0.92 GCK (0.36) ALDH1A1GRM4RAB9AADORA3L3MBTL1
SCHEMBL1340572 0.92 ALDH1A1 (0.38) ALDH1A1GRM4RAB9AL3MBTL1LMNA
SCHEMBL1343429 0.92 GRM4 (0.37) GRM4RAB9AGUSBKMT2ANPC1
SCHEMBL1340936 0.90 KMT2A (0.40) ALDH1A1GRM4KDM4ERAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45670-E1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2015-09-15 US disclosed
EP-2471533-A1 Aryl carbonyl derivatives as therapeutic agents Novo Nordisk A/S (DK) 2012-07-04 EP disclosed
US-20110301158-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS NOVO NORDISK A/S (DK) 2011-12-08 US disclosed
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-7541373-B2 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2009-06-02 US disclosed
US-7384967-B2 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-06-10 US disclosed
US-20080119454-A1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-05-22 US disclosed
US-20080119455-A1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-05-22 US disclosed
US-20060183783-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2006-08-17 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301158-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS GCK, GCKR, PDK2 ALDH1A1 192/4885GRM4 2551/4885KDM4E 992/4885
US-20080119455-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 ALDH1A1 192/4885GRM4 2551/4885KDM4E 992/4885
US-20060183783-A1 Aryl carbonyl derivatives as therapeutic agents GCK, PDK3, PDK4 ALDH1A1 148/4885GRM4 3123/4885KDM4E 1420/4885
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 ALDH1A1 192/4885GRM4 2551/4885KDM4E 992/4885
US-20080119454-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 ALDH1A1 192/4885GRM4 2551/4885KDM4E 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.